Vaccines for covid-19 patients

If you want to see all comparisons, please click here

BNT162b2 vs Placebo

Forest plots were updated on January 8th, 2021.
The Evidence profile and Summary of Findings table were updated on January 25th, 2021.

You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.

Forest plots

Trial subgroup analysis

Evidence profile

Summary of findings


Trial Comparisons Design Participants Sample size Overall risk of bias
Primary outcome
Full description
Treatment 1 Treatment 2
NCT04368728
BioNTech/Fosun Pharma/Pfizer
Polack FP,N Engl J Med,2020

Full text
Commentary
Commentary
Commentary
Commentary
Commentary
BNT162b2 Placebo RCT
Phase 2/3
Healthy SARS-CoV-2 DNA negative adults in multiple centres in Argentina, Brazil, Germany, South Africa, Turkey, and the USA N=43548
Some concerns
Details

Full description

The link in the column "Overall risk of bias" provides access to a complete description of the assessment of each risk of bias domain with supports for judgement produced using the Revised Cochrane risk-of-bias tool for randomized trials RoB 2.

The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column "Full description" provides access to the general characteristics of the study.

We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.